

<b>Name of the Issuer:</b>	<b>Global Health Limited</b>
----------------------------	------------------------------

<b>1 Type of Issue (IPO / FPO)</b>	IPO
<i>Source: Prospectus dated November 9, 2022</i>	

<b>2 Issue Size (Rs. Million)</b>	<b>22,055.70</b>
- Fresh Issue Size (Rs. Millions)	5,000.00
- Offer for Sale Component (Rs. Millions)	17,055.70
<i>Source: Prospectus dated November 9, 2022</i>	

<b>3 Grade of issue along with name of the rating agency</b>	
<b>Name</b>	Not Applicable
<b>Grade</b>	Not Applicable
<i>Source: Prospectus dated November 9, 2022</i>	

<b>4 Subscription Level (Number of times)</b>	<b>7.11*</b>
<i>Source: Final post issue report dated November 17, 2022</i>	
<i>*The above figure is after technical rejections</i>	

**5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges**

Particulars	%
(i) allotment in the issue <sup>(1)</sup>	40.29%
(ii) at the end of 1st Quarter immediately after the listing (December 31, 2022)	34.24%
(iii) at the end of 1st FY (March 31, 2023)	48.13%
(iv) at the end of 2nd FY (March 31, 2024)*	Not Available
(v) at the end of 3rd FY (March 31, 2025)*	Not Available

*\*QIB Holding not disclosed as reporting for the relevant period / fiscal year has not been completed.*

*(1) Source: Institutions (domestic + foreign) holding as disclosed in the stock exchange filing*

**6 Financials of the issuer**

Parameters	(In Rs. Millions)		
	1st FY (March 31, 2023)	2nd FY (March 31, 2024)*	3rd FY (March 31, 2025)*
Income from Operations	27,591.63	Not Available	Not Available
Net Profit for the period	3,260.79	Not Available	Not Available
Paid-up equity share capital	536.39	Not Available	Not Available
Reserves excluding revaluation reserves	23,745.69	Not Available	Not Available

*\*Financials not disclosed as reporting for the relevant fiscal year has not been completed.*

**7 Trading Status in the scrip of the issuer**

Company's Equity Shares are listed on both BSE Limited and National Stock Exchange of India Limited  
The Shares have not been suspended or delisted.

Particulars	Status
-------------	--------

(i) at the end of 1st FY (March 31, 2023)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2024)*	Not Available
(iii) at the end of 3rd FY (March 31, 2025)*	Not Available

\*Trading status not disclosed as the relevant fiscal year has not been completed.

#### 8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2023)	None	None
(ii) at the end of 2nd FY (March 31, 2024)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2025)*	Not Available	Not Available

\* Changes in Directors not disclosed as the relevant fiscal year has not been completed.

#### 9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

#### 10 Status of utilization of issue proceeds

##### To be utilised in FY 2023

(i) as disclosed in the offer document	Investment in two of our Subsidiaries, GHPPL and MHPL, in the form of debt or equity for repayment/prepayment of borrowings, in full or part, of such Subsidiaries General corporate purposes	3,750.00
	<b>Net Proceeds</b>	<b>4,767.01</b>
(ii) Actual utilization	None utilised*	
(iii) Reasons for deviation, if any	-	

\*source: monitoring agency report dated May 27, 2023

**11 Comments of monitoring agency**

(a) Comments on use of funds	None
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

**12 Pricing Data**

Issue Price (Rs.): 336  
Designated Stock Exchange: NSE  
Listing Date: 16-Nov-22

Price parameters	At close of listing day (November 16, 2022)	At close of 30th calendar day from listing day <sup>(1)</sup>	At close of 90th calendar day from listing day <sup>(2)(3)(4)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2023) <sup>(3)</sup>		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange <sup>(5)</sup>	415.30	447.65	456.75	526.95	526.95	414.15
NIFTY 50 <sup>(5)</sup>	18,409.65	18,414.90	17,770.90	17,359.75	18,812.50	15,293.50

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2024) <sup>(3)(4)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2025) <sup>(3)(4)</sup>		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange <sup>(5)</sup>	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50 <sup>(5)</sup>	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

Source: NSE website

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant period/ fiscal year has not completed

(5) In case of any reporting day falling on a holiday, next trading day prices/values have been disclosed.

**13 Basis for Issue Price**

Accounting ratio		As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2023)	At the end of 2nd FY (March 31, 2024) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2025) <sup>(2)</sup>
EPS	<b>Issuer:</b>				
	Consolidated (Diluted EPS)	7.77	12.58	Not Available	Not Available
	<b>Peer Group:</b>				
	Apollo Hospitals Enterprise Limited	73.24	56.97	Not Available	Not Available
	Fortis Healthcare Limited	7.35	7.80	Not Available	Not Available
	Max Healthcare Institute Limited	6.24	11.38	Not Available	Not Available
	Narayana Hrudayalaya Limited	16.84	29.85	Not Available	Not Available
Price to Earnings Ratio (P/E)	<b>Industry Avg:</b>	<b>25.92</b>	<b>26.50</b>	<b>N.A.</b>	<b>N.A.</b>
	<b>Issuer:</b>				
	Consolidated (Diluted)	43.24	41.89	Not Available	Not Available
	<b>Peer Group (Consolidated)</b>				
	Apollo Hospitals Enterprise Limited	59.44	75.67	Not Available	Not Available
	Fortis Healthcare Limited	39.11	33.32	Not Available	Not Available
	Max Healthcare Institute Limited	73.24	38.76	Not Available	Not Available
	Narayana Hrudayalaya Limited	43.82	25.93	Not Available	Not Available
	<b>Industry Avg:</b>	<b>53.90</b>	<b>43.42</b>	<b>N.A.</b>	<b>N.A.</b>
RoNW(%)	<b>Issuer:</b>				
	Consolidated	12.14%	13.43%	Not Available	Not Available
	<b>Peer Group: (Consolidated)</b>				
	Apollo Hospitals Enterprise Limited	18.86%	13.65%	Not Available	Not Available
	Fortis Healthcare Limited	11.27%	8.74%	Not Available	Not Available
	Max Healthcare Institute Limited	9.63%	14.89%	Not Available	Not Available
	Narayana Hrudayalaya Limited	22.97%	28.46%	Not Available	Not Available
NAV per Equity Share	<b>Industry Avg:</b>	<b>15.68%</b>	<b>16.43%</b>	<b>N.A.</b>	<b>N.A.</b>
	<b>Issuer:</b>				
	Consolidated	63.82	90.5388	Not Available	Not Available
	<b>Peer Group: (Consolidated)</b>				
	Apollo Hospitals Enterprise Limited	408.78	430.46	Not Available	Not Available
	Fortis Healthcare Limited	92.83	95.93	Not Available	Not Available
	Max Healthcare Institute Limited	64.79	76.31	Not Available	Not Available
	Narayana Hrudayalaya Limited	72.88	104.30	Not Available	Not Available
	<b>Industry Avg:</b>	<b>159.82</b>	<b>176.75</b>	<b>N.A.</b>	<b>N.A.</b>

**Notes:**

(1) Sourced from Prospectus dated November 9, 2022

(2) Information not provided as the relevant fiscal year has not completed

**14 Any other material information**

Date of disclosure	Announcement
13-Feb-23	Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements), 2015 (Listing Regulations)
14-Feb-23	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
27-Mar-23	Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements), 2015 (Listing Regulations)
11-May-23	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
27-May-23	Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2023
27-May-23	Statement Of Deviation/Variation In Utilization Of Funds Raised Through Initial Public Offer ('IPO')

27-May-23	Announcement under Regulation 30 (LODR)-Allotment
27-May-23	Disclosure Of Key Performance Indicators (Kpis)
23-Jun-23	Announcement under Regulation 30 (LODR)-Credit Rating
9-Aug-23	Announcement under Regulation 30 (LODR)-Allotment
10-Aug-23	Financial Results For Quarter Ended June 30, 2023
10-Aug-23	Announcement under Regulation 30 (LODR)-Joint Venture
10-Aug-23	Statement Of Deviation/Variation In Utilization Of Funds Raised Through Initial Public Offer ('IPO')
11-Aug-23	Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Source: BSE / NSE website

**Note:** The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable.

For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and / or [www.nseindia.com](http://www.nseindia.com).